AVITA Medical (NASDAQ:RCEL) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of AVITA Medical (NASDAQ:RCEL) in a report published on Friday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock.

Other equities analysts have also issued research reports about the company. Piper Sandler restated a “neutral” rating and set a $12.00 price target (up previously from $9.00) on shares of AVITA Medical in a research note on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 target price on shares of AVITA Medical in a research note on Tuesday, December 24th. Finally, Lake Street Capital cut their target price on AVITA Medical from $20.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

AVITA Medical Stock Performance

Shares of AVITA Medical stock opened at $10.57 on Friday. The firm has a market cap of $277.15 million, a P/E ratio of -4.74 and a beta of 1.55. The company has a current ratio of 3.73, a quick ratio of 3.37 and a debt-to-equity ratio of 3.48. AVITA Medical has a 12 month low of $7.51 and a 12 month high of $18.93. The stock’s fifty day moving average price is $10.69 and its 200-day moving average price is $10.59.

AVITA Medical (NASDAQ:RCEL) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.14). AVITA Medical had a negative net margin of 95.47% and a negative return on equity of 194.69%. On average, equities research analysts expect that AVITA Medical will post -2.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AVITA Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Huntington National Bank acquired a new stake in AVITA Medical in the third quarter worth about $32,000. FMR LLC boosted its holdings in AVITA Medical by 126.9% in the third quarter. FMR LLC now owns 4,248 shares of the company’s stock worth $46,000 after acquiring an additional 2,376 shares in the last quarter. Quest Partners LLC boosted its holdings in AVITA Medical by 269.4% in the third quarter. Quest Partners LLC now owns 7,520 shares of the company’s stock worth $81,000 after acquiring an additional 5,484 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in AVITA Medical in the second quarter worth about $86,000. Finally, Russell Investments Group Ltd. boosted its holdings in AVITA Medical by 48.0% in the fourth quarter. Russell Investments Group Ltd. now owns 7,164 shares of the company’s stock worth $92,000 after acquiring an additional 2,324 shares in the last quarter. Hedge funds and other institutional investors own 27.66% of the company’s stock.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.